EUCTR2010-020917-97-IT进行中（未招募）不适用
SPHERIC-1 (Sildenafil in the Chronic Obstructive Pulmonary Disease associated to Chronic Pulmonary Hypertension. Sixteen weeks long, multicentre, randomized, double blind study, in comparison with placebo, for the evaluation of sildenafil in the treatment of patients affected by pulmonary hypertension associated to COPD. - SPHERIC-1
ASSOCIAZIONE ITALIANA PNEUMOLOGI OSPEDALIERI0 个研究点开始时间: 2011年12月28日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patient affected by stable COPD under optimal treatment, chronic oxygen therapy in patients with hypoxia, with PaO2 at rest = 60 mmHg and PaCO2= 55 mmHg, aged between 18 and 80 years old: • Group 1: BPCO GOLD I-III (post bronchodilator FEV1 = 30%, FEV1/FVC = 0,7 , TLC = 70%) + PAPm = 30 mmHg and PCP <15 mmHg • Group 2: BPCO GOLD IV (post bronchodilator FEV1 <30%, FEV1/FVC = 0,7 , TLC = 70%) + PAPm = 35 mmHg and PCP <15 mmHg.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Different types of pulmonary hypertension (chronic, thromboembolic pulmonary hypertension, pulmonary arterial hypertension etc.) • Significant left cardiac disease (LVEF <45%, cardiomyopathy, valvulopathy, unstable coronaropathy) • Treatment with nitrates in the last 10 days, or in need of other nitrate therapy for different diseases • Treatment with other specific drugs for arterial pulmonary hypertension (less than 4 weeks) • Significant systemic disease other than COPD • Recent reacutization of chronic bronchitis (< 4 weeks) • Pregnancy or breastfeeding, or women without an adequate contraceptive method for the whole study duration • History of anaphylaxys or allergic reactions to 5-phosphodiesterase inhibitors • Cancers within the last 5 years with the exception of localized cancers of the skin or of the cervix • Hepatic insufficiency or chronic renal failure or hemoglobinemia < 10 g/dL during the screening phase • Contraindications to subministration as per SPC • Mental disorder, alcohol abuse, chronic alcoholism, drug abuse • Subjects unable to sign the informed consent form • Subjects unable to walk
研究者
相似试验
进行中（未招募）
不适用
SPHERIC-1OE: study of the duration of 12 months for the observation of the use of sildenafil for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease in patients enrolled in the previous study titled SPHERIC-1EUCTR2011-002018-35-ITASSOCIAZIONE ITALIANA PNEUMOLOGI OSPEDALIERI
进行中（未招募）
1 期
Sildenafil Treatment of COPD associated Pulmonary Hypertension - Sildenafil for PH in COPDPulmonary hypertension in patients with chronic obstructive lung disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDMedDRA version: 9.1Level: LLTClassification code 10037400Term: Pulmonary hypertensionEUCTR2008-002237-73-DKDept. of Pharmacology, Aarhus University
招募中
不适用
managment of oligohydramniosoligohydramniosPACTR201411000920150menoufiya university hospital184
进行中（未招募）
1 期
Estudio SIOVAC (Sildenafilo en Pacientes con Hipertensión Pulmonar tras Corrección de la Enfermedad Valvular)Pacientes con Hipertensión Pulmonar Secundaria a enfermedad valvular cardiacaEUCTR2007-007033-40-ESFundación para La Investigación Biomedica del Hospital Gregorio Marañón
进行中（未招募）
不适用
Therapy of PAH – Treatment with Sildenafil in Eisenmenger Patients - SildenafilPatients with pre-existing congenital heart disease may develop Eisenmenger physiology (EP), characterized by development of pulmonary arterial hypertension and intracardiac right to left shunt. This Patients suffer from cyanosis and reduced quality of life. While EP has been regarded as not amenable to conventional treatments, new oral drugs as Sildenafil have been used successfully to improve primary arterial hypertension. Thus may be an important treatment option for patients with EP, too.EUCTR2007-002774-64-DEDeutsches Herzzentrum Berlin, Kompetenznetz Angeborene Herzfehler80